about

Our Company

A global medical aesthetics company spanning aesthetics and therapeutics

MEDIFAB Co., Ltd. delivers science-backed total anti-aging solutions to the world — from professional clinical settings to everyday home care — under the vision of Clinic to Home, built on three proprietary ingredient platforms.

history

Our journey

2025

res novae Scalp MD: kFDA approval & FDA/CE Listing

Applied for clinical trial IND for chitosan LTG-Syno

Selected for govt-funded R&D project (USD 1.73M)

2024

Launched res novae beauty business division

Applied for clinical trial IND for chitosan LTG-S

Selected for govt-funded R&D project (USD 1.55M)

2023

Launched res novae product brand

Entered into export agreement (USD 5M)

Obtained regulatory approval from Thailand (Husteon)

2022

Selected for govt-funded R&D project (USD 0.44M)

Relocation & expansion, factory registration

Entered into export agreement (USD 2M)

Obtained KFDA approval for Husteon Mesh/Nasal

2021

Selected as "Innovation Enterprise National Representative 1000"

Obtained KFDA approval for Husteon Mesh

Completed FDA listing for Husteon Nasal

Launched Echrever (for export)

2020

Obtained medical device manufacturing license

Acquired export approval for Husteon

Obtained ISO 13485 certification

Selected for govt-funded R&D project (USD 1.7M)

2019

Govt-funded R&D project (USD 0.5M)

ISO9001, ISO14001 Certification

2018

Govt-funded R&D project (USD 0.6M)

Certified Venture Enterprise

2016

Medifab Incorporated

core value

Our Vision

MEDIFAB aims to become a globally recognized leader in medical aesthetics and anti-aging innovation. Grounded in our proprietary ingredient platforms and an expanding network of 50+ partners across North America, Greater China, the Middle East, and Europe, we are committed to setting new standards in anti-aging science and bringing the Clinic to Home philosophy to every corner of the world.

CEO

A message from
our CEO

Cha Mi-sun, CEO

Cha Mi-sun

CEO

MEDIFAB brings science-backed medical aesthetics to the world — from professional clinical settings to everyday home care — under our Clinic to Home vision.

Built on proprietary ingredient platforms, we will keep setting the standard for regenerative anti-aging.

global network

Global Expansion

Global partners

50+

N. America · China · Middle East · Europe

Greater China

3 live sessions with Xu Shan, KRW 1B+

MOU with Shanghai Yanxinuowei

res novae Core Impact initial export to Taiwan (2026)

Japan

Launched on Qoo10 & Rakuten via partner collaboration

Expanded reach through local influencer group-buy campaigns

Southeast Asia — Thailand

Filler export scheduled 2026 — identified as key regional hub

Middle East — Iraq

Filler export scheduled 2026

Europe · N. America · Global

Cosmoprof Bologna 2024 — 14+ companies & 200+ visitors

Dongkook Pharmaceutical OEM

50+ partner network incl. Russia